LuciGil 40 mg Tablet

Description

LuciGil (Gilteritinib) – a groundbreaking kinase inhibitor designed specifically for adult patients battling relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Each LuciGil tablet contains 44.2mg of Gilteritinib Fumarate, equating to 40mg of potent Gilteritinib, expertly formulated to target and inhibit the FLT3 pathway, a crucial contributor to AML progression. LuciGil offers an effective treatment option for those patients who have exhausted other therapies, providing hope and a new avenue for recovery. The recommended starting dose is 120 mg taken orally once daily, allowing for flexible administration with or without food, making it convenient for daily routines. In the absence of disease progression or unacceptable toxicity, a minimum treatment duration of 6 months is advised for optimal efficacy. Choose LuciGil for a targeted approach in your AML treatment journey and take a step towards reclaiming your health.